RecruitingPhase 1NCT05857969
Oncology
Dendritic cell sarcoma not otherwise specified
34
studies recruiting now
as of 7 Sept 2026
310
studies registered in total
as of 7 Sept 2026
10
countries with a recruiting site
as of 7 Sept 2026
21 Aug 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingNot applicableNCT07778212
Orelabrutinib Combined With Pola-R-CHP as First-Line Treatment for Patients With Intermediate- to High-Risk DLBCL
RecruitingPhase 3NCT07570823
A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
RecruitingPhase 1NCT06980116
Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
RecruitingPhase 3NCT07739654
Modified DHAP Versus Standard DHAP in Relapsed/Refractory Diffused Large B-cell Lymphoma.
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 34 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Dendritic cell sarcoma not otherwise specified study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Dendritic cell sarcoma not otherwise specified
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations.
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).